BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37408553)

  • 1. Understanding HIV-associated neurocognitive and neurodegenerative disorders (neuroAIDS): enroute to achieve the 95-95-95 target and sustainable development goal for HIV/AIDS response.
    Saxena SK; Sharma D; Kumar S; Puri B
    Virusdisease; 2023 Jun; 34(2):165-171. PubMed ID: 37408553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS.
    Kumar S; Maurya VK; Dandu HR; Bhatt ML; Saxena SK
    Biomol Concepts; 2018 May; 9(1):33-42. PubMed ID: 29742062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NeuroAIDS in sub-Saharan Africa: a clinical review.
    Alkali NH; Bwala SA; Nyandaiti YW; Danesi MA
    Ann Afr Med; 2013; 12(1):1-10. PubMed ID: 23480988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.
    Minagar A; Commins D; Alexander JS; Hoque R; Chiappelli F; Singer EJ; Nikbin B; Shapshak P
    Mol Diagn Ther; 2008; 12(1):25-43. PubMed ID: 18288880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS.
    Ahmed M; Iqubal A; Baboota S; Ali J
    Curr Top Med Chem; 2021; 21(12):1052-1066. PubMed ID: 33845745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV/neuroAIDS biomarkers.
    Rahimian P; He JJ
    Prog Neurobiol; 2017 Oct; 157():117-132. PubMed ID: 27084354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathogenesis of human immunodeficiency virus infection.
    Sillman B; Woldstad C; Mcmillan J; Gendelman HE
    Handb Clin Neurol; 2018; 152():21-40. PubMed ID: 29604978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of HIV-associated disease of the central nervous system.
    Mallard J; Williams KC
    Handb Clin Neurol; 2018; 152():41-53. PubMed ID: 29604983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.
    Nair M; Jayant RD; Kaushik A; Sagar V
    Adv Drug Deliv Rev; 2016 Aug; 103():202-217. PubMed ID: 26944096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.
    Hong S; Banks WA
    Brain Behav Immun; 2015 Mar; 45():1-12. PubMed ID: 25449672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global NeuroAIDS roundtable.
    Joseph J; Achim CL; Boivin MJ; Brew BJ; Clifford DB; Colosi DA; Ellis RJ; Heaton RK; Gallo-Diop A; Grant I; Kanmogne GD; Kumar M; Letendre S; Marcotte TD; Nath A; Pardo CA; Paul RH; Pulliam L; Robertson K; Royal W; Sacktor N; Sithinamsuwan P; Smith DM; Valcour V; Wigdahl B; Wood C
    J Neurovirol; 2013 Feb; 19(1):1-9. PubMed ID: 23354550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting the Therapeutic Relevance of Gene Therapy in NeuroAIDS: An Evolving Epidemic.
    Nabi B; Rehman S; Pottoo FH; Baboota S; Ali J
    Curr Gene Ther; 2020; 20(3):174-183. PubMed ID: 32538727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotypes of HIV-associated neurocognitive disorders based on viral and immune pathogenesis.
    Johnson TP; Nath A
    Curr Opin Infect Dis; 2022 Jun; 35(3):223-230. PubMed ID: 35665716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating viruses in the brain: Perspectives from NeuroAIDS.
    Nicol MR; McRae M
    Neurosci Lett; 2021 Mar; 748():135691. PubMed ID: 33524474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NeuroAIDS in children.
    Wilmshurst JM; Hammond CK; Donald K; Hoare J; Cohen K; Eley B
    Handb Clin Neurol; 2018; 152():99-116. PubMed ID: 29604987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.
    Sarma A; Das MK
    Mol Biomed; 2020; 1(1):15. PubMed ID: 34765998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Tobacco Smoke in HIV Progression: a Major Risk Factor for the Development of NeuroAIDS and Associated of CNS Disorders.
    Bhalerao A; Cucullo L
    Z Gesundh Wiss; 2020 Jun; 28(3):259-270. PubMed ID: 33738180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International NeuroAIDS: prospects of HIV-1 associated neurological complications.
    Trujillo JR; Jaramillo-Rangel G; Ortega-Martinez M; Penalva de Oliveira AC; Vidal JE; Bryant J; Gallo RC
    Cell Res; 2005; 15(11-12):962-9. PubMed ID: 16354575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings from the NIMH symposium on "NeuroAIDS in Africa: neurological and neuropsychiatric complications of HIV".
    Buch S; Chivero ET; Hoare J; Jumare J; Nakasujja N; Mudenda V; Paul R; Kanmogne GD; Sacktor N; Wood C; Royal W; Joseph J
    J Neurovirol; 2016 Oct; 22(5):699-702. PubMed ID: 27473196
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.